Browse studies

Find your next paid study

1 recruiting study matching your filters

A Double-Blind Crossover of KB803 and Matched Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa

KB803-EYE-01 is a Phase 3 double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of KB803 versus matched placebo in …

Dystrophic Epidermolysis BullosaDEB - Dystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis Bullosa+1 more

Estimated

~$10 – $8,750

Krystal Biotech, Inc.NCT07016750